Ultrasound contrast agent developer Acusphere of Cambridge, MA, has begun phase II clinical trials of its third-generation agent for assessing myocardial perfusion in patients with coronary artery disease (CAD). The company’s phase II trial will
Ultrasound contrast agent developer Acusphere of Cambridge, MA, has begun phase II clinical trials of its third-generation agent for assessing myocardial perfusion in patients with coronary artery disease (CAD). The companys phase II trial will evaluate the best imaging conditions for the assessment of myocardial perfusion in patients with CAD after a single dose of AI-700. Acusphere hopes that AI-700 could offer clinicians a low-cost alternative to nuclear medicine perfusion scans.
First-generation agents last for about a minute when illuminating the endocardium within the ventricles of the heart. Second-generation technology provides four or five minutes of continuous imaging in this application. Ultrasound contrast developers such as Acusphere hope that third-generation agents will extend imaging time to 20 to 30 minutes, or about the time of a cardiac ultrasound examination (SCAN 6/23/99).
Studies have suggested that AI-700 could be used in a continuous mode, allowing clinicians to overcome some of the shortcomings of other agents, which have short persistence times because their contrast-enhancing microbubbles break up under ultrasound beams, according to the company (SCAN 4/14/99). Acusphere believes that the AI-700 microbubbles may have longer persistence times because they are made from synthetic polymers.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
The Reading Room Podcast: A Closer Look at Remote MRI Safety, Part 2
July 25th 2025In the second of a multi-part podcast episode, Emanuel Kanal, M.D. and Tobias Gilk, MRSO, MRSE, share their perspectives on remote MRI safety protocols for ensuring screening accuracy and adherence to conditional implant guidelines as well as a rapid and effective response to adverse events.
Twenty Years of CT Colonography for Colorectal Cancer Screening: What the Research Reveals
July 29th 2025Computed tomography colonography (CTC) demonstrated a 91.6 percent positive predictive value (PPV) for polyps > 6 mm, according to new research involving over 9,000 patients who underwent CTC for primary asymptomatic colorectal cancer screening.
The Reading Room Podcast: Current and Emerging Insights on Abbreviated Breast MRI, Part 2
July 23rd 2025In the second part of a multi-part podcast episode, Stamatia Destounis, MD, Emily Conant, MD and Habib Rahbar, MD, discuss key sequences for abbreviated breast MRI and how it stacks up to other breast cancer screening modalities.